Efficient Identification of Human Immunodeficiency Virus Type 1 Mutants Resistant to a Protease Inhibitor by Using a Random Mutant Library
Authors:
- 1 November 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (11) , 5090-5098
Abstract
Emergence of drug-resistant mutant viruses during the course of antiretroviral therapy is a major hurdle that limits the success of chemotherapeutic treatment to suppress human immunodeficiency virus type 1 (HIV-1) replication and AIDS progression. Development of new drugs and careful patient management based on resistance genotyping data are important for enhancing therapeutic efficacy. However, identifying changes leading to drug resistance can take years of clinical studies, and conventional in vitro assays are limited in generating reliable drug resistance data. Here we present an efficient in vitro screening assay for selecting drug-resistant variants from a library of randomly mutated HIV-1 strains generated by transposon-directed base-exchange mutagenesis. As a test of principle, we screened a library of mutant HIV-1 strains containing random mutations in the protease gene by using a reporter T-cell line in the presence of the protease inhibitor (PI) nelfinavir (NFV). Analysis of replicating viruses from a single round of infection identified 50 amino acid substitutions at 35 HIV-1 protease residue positions. The selected mutant viruses showed specific resistance to NFV and included most of the known NFV resistance mutations. Therefore, the new assay is efficient for identifying changes leading to drug resistance. The data also provide insights into the molecular mechanisms underlying the development of drug resistance.Keywords
This publication has 44 references indexed in Scilit:
- HIV-1 Protease Mutations and Protease Inhibitor Cross-ResistanceAntimicrobial Agents and Chemotherapy, 2010
- Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistanceProceedings of the National Academy of Sciences of the United States of America, 2010
- Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment EfficacyPLOS Medicine, 2008
- Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742Antimicrobial Agents and Chemotherapy, 2008
- Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within PatientsJournal of Virology, 2007
- Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistanceGenome Research, 2007
- DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutationsNucleic Acids Research, 2007
- Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug ResistanceJournal of Chemical Theory and Computation, 2005
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Expanded HIV-1 Cellular Tropism by Phenotypic Mixing with Murine Endogenous RetrovirusesScience, 1990